AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Other Events

Item 8.01 Other Events.

For purposes of the registration statement on FormS-3 (File
No.333-202252) (the Registration Statement) filed by AMAG
Pharmaceuticals,Inc. (the Company), the computation of the ratio
of earnings to fixed charges of the Company for the three months
ended March31, 2017 and the years ended December31, 2016,
December31, 2015, December31, 2014, December31, 2013 and
December31, 2012 is filed herewith as Exhibit12.1 and is
incorporated by reference into this Current Report on Form8-K and
the Registration Statement.

Item 9.01. Financial Statements and Exhibits

d) Exhibits.

About AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Recent Trading Information

AMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) closed its last trading session down -0.95 at 20.50 with 2,959,633 shares trading hands.